Compare Mesoblast Limited (MESO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs United States Natural Gas Fund — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while United States Natural Gas Fund trades at $10.84 (market cap $517.27M). The key difference: Mesoblast Limited is far larger — about 3.4× United States Natural Gas Fund's market cap, and Mesoblast Limited is more actively traded (239,027 versus 29,485,537). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and United States Natural Gas Fund for 22 Days on average.
| MESO | UNG | |
|---|---|---|
Market Cap | $1.75B | $517.27M |
Volume | 239,027 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $20.96 | $16.90 |
52-Week Low | $13.19 | $9.63 |
Typical Hold Time | 14 Days | 22 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported a net income of $65.15 million in 2024 with no revenue, while cash flow from operations was positive at $47.54 million. Recent news highlights natural gas price volatility driven by record U.S. production and geopolitical tensions in the Middle East.
The outlook is mixed: strong profitability and low debt support fundamentals, but zero revenue and negative net cash flow pose risks. Geopolitical events and weather-dependent demand create volatility, making the stock sensitive to energy market shifts. Analyst sentiment is cautiously optimistic given the bullish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
